2191 Hyperfractionated radiotherapy (2100 cGY) for stage 4 neuroblastoma as part of intensive multimodality therapy
Smitha Gollamudi(Memorial Sloan Kettering Cancer Center), N K Cheung(Memorial Sloan Kettering Cancer Center), Brian H. Kushner(Memorial Sloan Kettering Cancer Center), Karen L. Lindsley(Memorial Sloan Kettering Cancer Center), Michael P. LaQuaglia(Memorial Sloan Kettering Cancer Center), T.E. Merchant(St. Jude Children's Research Hospital), Nancy S. Rosenfield(Memorial Sloan Kettering Cancer Center), K. Krämer(Memorial Sloan Kettering Cancer Center), Steven B. Abramson(NYU Langone Health)
International Journal of Radiation Oncology*Biology*Physics
January 1, 1997
Cited by 0
Related Papers
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
|Journal of Clinical Oncology|1987|417
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
|Nature Communications|2022|219